Gain Therapeutics presents Phase 1b data showing stable MDS-UPDRS and biomarker improvements for GT-02287 at AD/PD 2026

Gain Therapeutics, Inc.

Phase 1b: 19 completed Part 1, 16 entered extension; DMC approved continuation without changes.
MDS-UPDRS scores stable over 150 days; high GluSph group showed 6.7-point difference vs low group.
DDC decreased after 90 days in high GluSph baseline group, supporting disease-modifying potential.
Preclinical data for novel GCase modulator GT-04686 presented, ready for IND-enabling studies.
Extension study expected to complete September 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.